Stock Scorecard
Stock Summary for Autolus Therapeutics plc (AUTL) - $6.24 as of 3/28/2024 3:32:39 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AUTL
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AUTL
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AUTL
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for AUTL
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for AUTL
Financial Details for AUTL
Company Overview |
|
---|---|
Ticker | AUTL |
Company Name | Autolus Therapeutics plc |
Country | USA |
Description | Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/1/2024 |
Stock Price History |
|
Last Day Price | 6.24 |
Last Day Price Updated | 3/28/2024 3:32:39 PM EST |
Last Day Volume | 412,935 |
Average Daily Volume | 1,393,307 |
52-Week High | 7.45 |
52-Week Low | 1.61 |
Last Price to 52 Week Low | 287.58% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 66.35 |
Sector PE | 60.76 |
5-Year Average PE | -4.98 |
Free Cash Flow Ratio | 6.93 |
Industry Free Cash Flow Ratio | 17.10 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 6.15 |
Total Cash Per Share | 0.90 |
Book Value Per Share Most Recent Quarter | 0.64 |
Price to Book Ratio | 14.72 |
Industry Price to Book Ratio | 7.21 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 966.29 |
Industry Price to Sales Ratio Twelve Trailing Months | 32.37 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 265,926,000 |
Market Capitalization | 1,659,378,240 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -40.01% |
Reported EPS 12 Trailing Months | -1.20 |
Reported EPS Past Year | -0.45 |
Reported EPS Prior Year | -0.98 |
Net Income Twelve Trailing Months | -208,395,000 |
Net Income Past Year | -208,383,000 |
Net Income Prior Year | -148,839,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | 113.88% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 239,566,000 |
Total Cash Past Year | 239,566,000 |
Total Cash Prior Year | 256,415,000 |
Net Cash Position Most Recent Quarter | 239,566,000 |
Net Cash Position Past Year | 239,566,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 111,474,000 |
Total Stockholder Equity Prior Year | 180,518,000 |
Total Stockholder Equity Most Recent Quarter | 111,474,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.03 |
MACD Signal | -0.07 |
20-Day Bollinger Lower Band | 4.19 |
20-Day Bollinger Middle Band | 5.81 |
20-Day Bollinger Upper Band | 7.43 |
Beta | 1.89 |
RSI | 57.20 |
50-Day SMA | 3.87 |
200-Day SMA | 5.65 |
System |
|
Modified | 3/27/2024 6:29:38 PM EST |